Ticker League

EBITDA Margin for Vertex Pharmaceuticals (VRTX)

As of · Reported

Metric

TTM

42.3%

YoY change

+36.73pp

Trough year (2009)

-586.9%

Peak year (2020)

52.9%

EBITDA Margin history chart for Vertex Pharmaceuticals (VRTX) from 1990 to 2025

Latest: 41.1%

EBITDA Margin change chart for Vertex Pharmaceuticals (VRTX) from 1990 to 2025

Latest: +36.73pp

EBITDA Margin history table for Vertex Pharmaceuticals (VRTX) from 1990 to 2025

  • 202541.1%+36.73pp
  • 20244.4%-42.25pp
  • 202346.7%-3.00pp
  • 202249.7%+11.15pp
  • 202138.5%-14.41pp
  • 202052.9%+15.44pp
  • 201937.5%+14.29pp
  • 201823.2%+19.04pp
  • 20174.1%-0.28pp
  • 20164.4%+44.27pp
  • 2015-39.8%+63.32pp
  • 2014-103.2%-57.39pp
  • 2013-45.8%-48.55pp
  • 20122.8%-6.71pp
  • 20119.5%+501.15pp
  • 2010-491.7%+95.20pp
  • 2009-586.9%-344.02pp
  • 2008-242.8%-49.27pp
  • 2007-193.6%-101.35pp
  • 2006-92.2%-21.08pp
  • 2005-71.1%+33.61pp
  • 2004-104.7%+277.84pp
  • 2003-382.6%-306.20pp
  • 2002-76.4%-18.39pp
  • 2001-58.0%-26.44pp
  • 2000-31.6%+40.36pp
  • 1999-71.9%+25.38pp
  • 1998-97.3%-61.68pp
  • 1997-35.6%+237.32pp
  • 1996-272.9%-169.76pp
  • 1995-103.2%-15.41pp
  • 1994-87.8%-106.03pp
  • 199318.3%+207.75pp
  • 1992-189.5%-70.72pp
  • 1991-118.8%+59.51pp
  • 1990-178.3%—

EBITDA Margin values are taken from Vertex Pharmaceuticals's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About EBITDA Margin at Vertex Pharmaceuticals (VRTX)

According to Vertex Pharmaceuticals's latest reported financial statements, the company's latest reported EBITDA margin is 42.3%. EBITDA margin is EBITDA divided by revenue — earnings before interest, taxes, depreciation, and amortization as a percentage of sales. By stripping out non-cash charges and capital-structure effects, it approximates operating cash profitability and is widely used to compare companies with different asset bases and leverage.

Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .

In 2025, Vertex Pharmaceuticals (VRTX) EBITDA margin totalled 41.14% – expanded 36.7 percentage points year-over-year.

2020 marks the peak EBITDA margin at 52.93%, with the historical low of -586.85% recorded in 2009.

Vertex Pharmaceuticals EBITDA Margin by Year

Vertex Pharmaceuticals EBITDA Margin 2025: 41.1%

2025's EBITDA margin for Vertex Pharmaceuticals came in at 41.14%, expanded 36.7 percentage points from 2024.

Vertex Pharmaceuticals EBITDA Margin 2024: 4.4%

Vertex Pharmaceuticals posted EBITDA margin of 4.41% in 2024, contracted 42.2 percentage points from 2023.

Vertex Pharmaceuticals EBITDA Margin 2023: 46.7%

In 2023, Vertex Pharmaceuticals reported EBITDA margin of 46.66%, contracted 3.0 percentage points from 2022.

Vertex Pharmaceuticals EBITDA Margin 2022: 49.7%

Vertex Pharmaceuticals EBITDA margin in 2022 was 49.67%, expanded 11.1 percentage points from 2021.

Vertex Pharmaceuticals EBITDA Margin 2021: 38.5%

Vertex Pharmaceuticals EBITDA margin in 2021 was 38.52%.

See more financial history for Vertex Pharmaceuticals (VRTX).

Sector peers by EBITDA Margin

Healthcare peers of Vertex Pharmaceuticals (VRTX), ranked by their latest EBITDA margin

Frequently asked questions

Vertex Pharmaceuticals (VRTX) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Capital Return

No dividends paid by this company.